Long-Term Pancreatic Allograft Survival After Renal Retransplantation in Prior Simultaneous Pancreas-Kidney Recipients

Division of Transplantation, University of Maryland School of Medicine, University of Maryland, Baltimore, MD, USA.
American Journal of Transplantation (Impact Factor: 5.68). 01/2012; 12(4):937-46. DOI: 10.1111/j.1600-6143.2011.03916.x
Source: PubMed


Over a 23-year period, our center performed 82 renal retransplants in prior simultaneous pancreas-kidney recipients with functioning pancreatic allografts. All patients were insulin-independent at retransplantation. We aimed to quantify the risk of returning to insulin therapy and to identify factors that predispose patients to pancreatic allograft failure after renal retransplantation. Among these 82 patients, pancreatic allograft survival after renal retransplantation was 78%, 49% and 40% at 1, 5 and 10 years. When analyzing risk factors, we unexpectedly found no clear relationship between the cause of primary renal allograft failure, hemoglobin A1c (HbA1c) or fasting C-peptide level at retransplant and subsequent pancreatic allograft failure. An elevated HbA1c in the month after renal retransplant correlated with subsequent pancreatic graft loss and patients experiencing pancreatic graft loss were more likely to subsequently lose their renal retransplant. Although it is difficult to prospectively identify those patients who will return to insulin therapy after repeat renal transplantation, the relatively high frequency of this event mandates that this risk be conveyed to patients. Nonetheless, the survival benefit associated with renal retransplantation justifies pursuing retransplantation in this population.

Download full-text


Available from: Jon Odorico, Oct 17, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: A syndrome of rapid-onset end-stage renal disease (SORO-ESRD) following acute kidney injury (AKI) in native kidneys was described recently. To what extent this syndrome of unanticipated and rapidly irreversible ESRD impacts renal allograft survival is unknown. Over 6 months, we managed two deceased donor renal transplant recipients (RTRs) with rapid acceleration of previously stable allograft chronic kidney disease to abruptly terminate in irreversible ESRD following AKI. These are the first reports of SORO-ESRD in RTRs. More research is needed to ascertain the contribution of SORO-ESRD to renal allograft loss.
    No preview · Article · May 2013 · Indian Journal of Nephrology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal retransplantation after a failed prior kidney and pancreas transplant is being increasingly performed. In these complex cases, both iliac fossae have been used for prior transplants, and the placement of the new allograft can be problematic. We describe our experience with an alternative technique for renal retransplantation in the setting of severe bilateral aortoiliac atherosclerosis or scarring and fibrosis on the iliac vessels. Nephrectomy of the failed allograft is performed, and the renal vessels of the failed allograft are preserved. The new kidney is implanted on renal vessels of the failed allograft at the same operative time. This technique was attempted and successfully accomplished in a total of 6 patients (mean operative time = 240 ± 63 min). One postoperative complication occurred: poor arterial inflow to the allograft, being corrected reoperatively. Hospitalizations ranged from 5 to 8 days. Five out of the six patients were alive with a functioning allograft at last follow-up (a single graft failure occurred 21 months postoperatively in the setting of posttransplant lymphoproliferative disease that also led to patient death). Renal vessels of the failed allograft seem to be suitable alternative vascular conduits for renal retransplantation after prior kidney and pancreas transplants. This article is protected by copyright. All rights reserved.
    No preview · Article · Mar 2014 · Clinical Transplantation
  • [Show abstract] [Hide abstract]
    ABSTRACT: Successful pancreas-kidney transplantation liberates patients from dialysis and re-establishes normoglycemic regulation in select patients with type 1 diabetes. Benefit to the recipient must be balanced against surgical morbidity, the adverse effects of life-long immunosuppression and regional waiting times. Data has shown that 5-, 10-, and 20-year graft function rates are 80%, 68% and 45%, respectively, for pancreas-kidney transplants; 62%, 46% and 16%, respectively, for pancreas after kidney transplants; 59%, 39%, and 12%, respectively, for pancreas transplants alone. Anastomotic leak and graft thrombosis decrease graft survival while cardiovascular events represent the major cause of death. Pancreas transplantation appears to ameliorate some of the secondary complications of diabetes but appropriately controlled studies are difficult to perform. Combined pancreas-kidney transplantation should be offered as the primary option in type 1 diabetic patients with diabetic nephropathy who are not yet on dialysis.
    No preview · Chapter · Jul 2014
Show more